GlassScriptPhysician profile
James D Mcdonald
NPI 1912393588
$584.55
in general payments reported to CMS, 2019-2025
13 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $15.67 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.06 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $138.70 | 2025 | Arista |
| Ethicon US, LLC | $106.83 | 2025 | Ethicon, Vistaseal, Surgiflo Hemostatic Matrix |
| Merck Sharp & Dohme LLC | $81.48 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Stryker Corporation | $38.55 | 2025 | Molli, Eikon Lt Adapt Smoke Evacuation |
| Acera Surgical, INC. | $25.52 | 2025 | Restrata Wound Matrix |
| Regeneron Healthcare Solutions, INC. | $22.85 | 2025 | Libtayo |
| Lilly USA, LLC | $20.47 | 2025 | Verzenio |
| Caris Mpi, INC. | $20.06 | 2025 | Mi Cancer Seek |
| Kerecis Limited | $17.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Pfizer INC. | $15.67 | 2024 | |
| Janssen Biotech, INC. | $14.29 | 2025 | Tecvayli |
| Genentech USA, INC. | $14.14 | 2025 | Itovebi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.